PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Taherzadeh Fard, Elahe ^a   Saft, Carsten ^b   Akkad, Denis A ^a   Wieczorek, Stefan ^a   Haghikia, Aiden ^b   Chan, Andrew ^b   Epplen, Jörg T ^a   Arning, Larissa ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR NRF1;

ARTICLE; CHROMOSOME 10Q; CHROMOSOME 4P; CHROMOSOME 7Q; CONTROLLED STUDY; DNA MODIFICATION; DOWNSTREAM PROCESSING; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR MEMBRANE; LEUKOCYTE; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; PATHOGENESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79956049960     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-32     Document Type: Article

References (40)

1. A novel gene containing a trinucleotide repeat that is unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell 1993 26 971 983
2. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. RG Snell JC MacMillan JP Cheadle I Fenton LP Lazarou P Davies ME MacDonald JF Gusella PS Harper DJ Shaw, Nat Genet 1993 4 393 397 10.1038/ng0893-393 8401588 (Pubitemid 23231489)
3. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. SE Andrew YP Goldberg B Kremer H Telenius J Theilmann S Adam E Starr F Squitieri B Lin MA Kalchman,, et al. Nat Genet 1993 4 398 403 10.1038/ng0893-398 8401589 (Pubitemid 23231490)
4. Trinucleotide repeat length instability and age of onset in Huntington's disease. M Duyao C Ambrose R Myers A Noveletto F Persichetti M Frontali S Folstein C Ross M Franz M Abbott,, et al. Nat Genet 1993 4 387 392 10.1038/ng0893-387 8401587 (Pubitemid 23231488)
5. Huntington's disease: the case for genetic modifiers. JF Gusella ME Macdonald, Genome Med 2009 1 80 10.1186/gm80 19725930
6. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. JM Andresen J Gaya'n SS Cherny D Brocklebank G Alkorta-Aranburu EA Addis US-Venezuela Collaborative Research Group LR Cardon DE Housman NS Wexler, J Med Genet 2007 44 44 50 17018562 (Pubitemid 46142838)
7. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. L Arning PH Kraus S Valentin C Saft J Andrich JT Epplen, Neurogenetics 2005 6 25 28 10.1007/s10048-004-0198-8 15742215 (Pubitemid 40394827)
8. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. L Arning D Monté W Hansen S Wieczorek P Jagiello DA Akkad J Andrich PH Kraus C Saft JT Epplen, J Mol Med 2008 86 485 490 10.1007/s00109-007-0299-6 18327563
9. Huntingtin-associated protein-1 is a modifier of the ageat - onset of Huntington's disease. S Metzger J Rong HP Nguyen A Cape J Tomiuk AS Soehn P Propping Y Freudenberg-Hua J Freudenberg L Tong,, et al. Hum Mol Genet 2008 17 1137 1146 10.1093/hmg/ddn003 18192679 (Pubitemid 351494185)
10. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. E Taherzadeh-Fard C Saft S Wieczorek JT Epplen L Arning, Neurogenetics 2010 4 435 439
11. The gene coding for PGC-1alpha modifies age at onset in Huntington's disease. P Weydt SM Soyal C Gellera S Didonato C Weidinger H Oberkofler GB Landwehrmeyer W Patsch, Mol Neurodegener 2009 4 3 10.1186/1750-1326-4-3 19133136
12. PGC-1alpha as modifier of onset age in Huntington disease. E Taherzadeh-Fard C Saft J Andrich S Wieczorek L Arning, Mol Neurodegener 2009 4 10 10.1186/1750-1326-4-10 19200361
13. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. L Arning A Haghikia E Taherzadeh-Fard C Saft J Andrich B Pula S Höxtermann S Wieczorek DA Akkad M Perrech R Gold JT Epplen A Chan, J Mol Med 2010 4 431 436
14. Localization of sequence variations in PGC-1 influence their modifying effect in Huntington disease. HV Che S Metzger E Portal C Deyle O Riess HP Nguyen, Mol Neurodegener 2011 6 1 10.1186/1750-1326-6-1 21211002
15. The role of PGC-1 in the pathogenesis of neurodegenerative disorders. K Rána-Vörös P Weydt, Curr Drug Targets 2010 10 1262 1269
16. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. J Lin PH Wu PT Tarr KS Lindenberg J St-Pierre CY Zhang VK Mootha S Jäger CR Vianna RM Reznick,, et al. Cell 2004 119 121 135 10.1016/j.cell.2004.09.013 15454086 (Pubitemid 39349325)
17. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. TC Leone JJ Lehman BN Finck PJ Schaeffer AR Wende S Boudina M Courtois DF Wozniak N Sambandam C Bernal-Mizrachi,, et al. PLoS Biol 2005 4 101
18. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. L Cui H Jeong F Borovecki CN Parkhurst N Tanese D Krainc, Cell 2006 127 59 69 10.1016/j.cell.2006.09.015 17018277 (Pubitemid 44466642)
19. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. P Weydt VV Pineda AE Torrence RT Libby TF Satterfield ER Lazarowski ML Gilbert GJ Morton TK Bammler AD Strand,, et al. Cell Metab 2006 4 349 362 10.1016/j.cmet.2006.10. 004 17055784 (Pubitemid 44645069)
20. Impaired PGC-1alpha function in muscle in Huntington's disease. RK Chaturvedi P Adhihetty S Shukla T Hennessy N Calingasan L Yang A Starkov M Kiaei M Cannella J Sassone A Ciammola F Squitieri MF Beal, Hum Mol Genet 2009 16 3048 3065
21. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. RK Chaturvedi NY Calingasan L Yang T Hennessey A Johri MF Beal, Hum Mol Genet 2010 16 3190 3205
22. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. DJ Ho NY Calingasan E Wille M Dumont MF Beal, Exp Neurol 2010 1 74 84
23. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. RC Scarpulla, Biochim Biophys Acta 2002 1-2 1 14 (Pubitemid 34597079)
24. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. RC Scarpulla, Biochim Biophys Acta 2010
25. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. DP Kelly RC Scarpulla, Genes Dev 2004 4 357 368 (Pubitemid 38316342)
26. NRF-2 transcription factor is required for human TOMM20 gene expression. JR Blesa JA Prieto-Ruiz JM Hernndez J Hernndez-Yago, Gene 2007 1-2 198 208 (Pubitemid 46356798)
27. Quantitative analysis of circulating mitochondrial DNA in plasma. RW Chiu LY Chan NY Lam NB Tsui EK Ng TH Rainer YM Lo, Clin Chem 2003 5 719 726 (Pubitemid 36513249)
28. Physical activity as a metabolic stressor. EF Coyle, Am J Clin Nutr 2000 72 512S 520S 10919953 (Pubitemid 30650049)
29. NRF-1 genotypes and endurance exercise capacity in young Chinese men. Z He Y Hu L Feng Y Li G Liu Y Xi L Wen A Lucia, Br J Sports Med 2008 5 361 366 (Pubitemid 351702683)
30. PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. A Lucia F Gámez-Gallego I Barroso M Rabadn F Bandrés AF San Juan JL Chicharro U Ekelund S Brage CP Earnest,, et al. J Appl Physiol 2005 1 344 348 (Pubitemid 40934501)
31. Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. AK Niemi K Majamaa, Eur J Hum Genet 2005 13 965 969 10.1038/sj.ejhg.5201438 15886711 (Pubitemid 41131745)
32. Mitochondrial haplogroup T is negatively associated with the status of elite endurance athlete. MG Castro N Terrados JR Reguero V Alvarez E Coto, Mitochondrion 2007 7 354 357 10.1016/j.mito.2007.06.002 17660050 (Pubitemid 47307255)
33. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. N Stefan C Thamer H Staiger F Machicao J Machann F Schick C Venter A Niess M Laakso A Fritsche,, et al. J Clin Endocrinol Metab 2007 92 1827 1833 10.1210/jc.2006-1785 17327385 (Pubitemid 46997196)
34. Association of mitochondrial transcription factor (TFAM) gene polymorphism with physical performance in athletes. II Ahmetov DV Popov SS Missina OL Vinogradova VA Rogozkin, Human Physiology 2010 36 229 233 10.1134/S0362119710020155
35. The biology of PGC-1alpha and its therapeutic potential. C Handschin, Trends Pharmacol Sci 2009 6 322 329
36. Targeting PGC-1 alpha to control energy homeostasis. Z Wu O Boss, Expert Opin Ther Targets 2007 10 1329 1338 (Pubitemid 47604072)
37. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. P Jagiello M Gencik L Arning S Wieczorek E Kunstmann E Csernok WL Gross JT Epplen, Hum Genet 2004 5 468 477 (Pubitemid 38678925)
38. The structure of haplotype blocks in the human genome. SB Gabriel SF Schaffner H Nguyen JM Moore J Roy B Blumenstiel J Higgins M DeFelice A Lochner M Faggart,, et al. Science 2002 296 2225 2229 10.1126/science.1069424 12029063 (Pubitemid 34680308)
39. NRF2 genotype improves endurance capacity in response to training. Z He Y Hu L Feng Y Lu G Liu Y Xi L Wen LR McNaughton, Int J Sports Med 2007 9 717 721 (Pubitemid 47414159)
40. SIRT1 gene, age-related diseases, and mortality: the Leiden 85-plus study. M Kuningas M Putters RG Westendorp PE Slagboom D van Heemst, J Gerontol A Biol Sci Med Sci 2007 9 960 965 (Pubitemid 47531211)